G01N 2333/7155
For interleukins [il]
Official title: for interleukins [IL]
G01N2333/7155 (For interleukins [il]) appears on 148 US grants and 296 published applications in this corpus.
Search patents in G01N- Granted patents
- 148
- Published applications
- 296
- Assignees
- 168
- Inventors
- 569
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 2 |
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 2 | 3 |
| 2009 | 0 | 4 |
| 2010 | 3 | 7 |
| 2011 | 4 | 9 |
| 2012 | 6 | 12 |
| 2013 | 6 | 16 |
| 2014 | 6 | 9 |
| 2015 | 4 | 28 |
| 2016 | 5 | 14 |
| 2017 | 14 | 17 |
| 2018 | 14 | 26 |
| 2019 | 14 | 19 |
| 2020 | 18 | 18 |
| 2021 | 12 | 15 |
| 2022 | 12 | 18 |
| 2023 | 4 | 24 |
| 2024 | 3 | 15 |
| 2025 | 15 | 21 |
| 2026 | 6 | 14 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Drug-specific pharmacokinetic assay for IL-15 superagonist6 Oct 2026US 12,754,189 B2NantCell, Inc.
- Method of treating ichthyosis in a subject by administering an anti-interleukin 36 receptor (IL-36R) binding agent25 Aug 2026US 12,715,924 B2AnaptysBio, Inc.
- Composition for cancer diagnosis18 Aug 2026US 12,710,425 B2Acurasysbio Co., Ltd.
- Cytokine-based therapies and methods30 Jun 2026US 12,668,627 B2Reverb Therapeutics, Inc.
- Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function31 Mar 2026US 12,590,160 B2Cedars-Sinai Medical Center
- Multi-Analyte Rapid Diagnostic Test for Sepsis Using Novel Biomarkers and Quantum Dot Technology1 Oct 2026US 2026/0298921 A1Trimar Domestic Inc.
- Novel cytokine-based therapies and methods17 Sep 2026US 2026/0274943 A1Reverb Therapeutics, Inc.
- Photonic crystal biochip and protein detection method thereof20 Aug 2026US 2026/0243759 A1Beijing Institute of Heart Lung and Blood Vessel Diseases
- Potency Assay and Manufacturing Method6 Aug 2026US 2026/0224634 A1Mesoblast International Sarl
- A heterohybridoma-based method of generating recombinant rabbit monoclonal antibodies and antibodies produced by method16 Jul 2026US 2026/0201046 A1Bio-Rad Laboratories, Inc.
Most cited
By later US patents
- Prostaglandin E2 dual variable domain immunoglobulins and uses thereof85US 8,822,645 B2AbbVie Inc. · 2014
- IL1RL-1 as a cardiovascular disease marker and therapeutic target48US 7,670,769 B2The Brigham and Women S Hospital, Inc. · 2010
- Methods for diagnosis of cardiovascular disease47US 7,432,060 B2The Brigham and Women S Hospital, Inc. · 2008
- Predicting risk of major adverse cardiac events47US 8,090,562 B2Critical Care Diagnostics, Inc. · 2012
- Predicting mortality and detecting severe disease43US 7,998,683 B2Critical Care Diagnostics, Inc. · 2011